Select Page
Pharma & COVID19: Winners, losers, prospects
EPHA #A2MDialogues

19 November 2020

16:00-17:00 CET

online

Our third dialogue in a series of online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.

Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe. 

Is the affordability debate in Europe changing in the light of COVID19?

Who are the big winners and losers?

From the onset of the COVID19 pandemic, governments turned to the pharmaceutical sector for answers and solutions. Almost a year later, we look at how the present pandemic has reshaped the dynamics within the sector, as well as the power balance between this diverse business sector and European governments. What are the trends for the near future?

We will hear from a venture capitalist investing in pharma, a leading access to medicines advocate, an expert in the science and economics of drug R&D, and the advocacy director of an alternative drug development model.

 

Panelists

Andrew Elder 

Deputy Managing Partner

Albion VC

Dr Els Torreele

Visiting Policy Fellow, Institute for Innovation and Public Purpose

Jack Scannell

Innogen Associate & Honorary Fellow, School of Social and Political Science

University of Edinburgh

Michelle Childs

Director of Policy Advocacy 

DNDi

Moderated by

Yannis Natsis,

Policy Manager, Universal Access to Affordable Medicines

European Public Health Alliance

Join our panelists to discuss 

Is pharma benefiting from the circumstances created by the pandemic?

What are the risks for governments and the industries?

What have been the key opportunities for industry from the pandemic?

What opportunities and risks do investors see?  

Is self-sufficiency the right path for Europe?

Find out more about the other #A2MDialogues in the series below

Unleashing meaningful innovation through regulatory reform

19 October 2020

The EU's IP strategy: Enabler or barrier?

27 October 2020

The Presidencies’ perspective on the pharmaceutical strategy: Europe’s to-do list on access to medicines

25 November 2020

16:00-17:00 CET

Follow on social media

#A2MDialogues

#A2Msolutions

Contact

Yannis Natsis

Policy Manager, Universal Access and Affordable Medicines, EPHA
yannis@epha.org